BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38493755)

  • 1. Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
    Wan CL; Huang YH; Huang SM; Xu YL; Tan KW; Yan-Qiu ; Shen XD; Ge SS; Cao HY; Li YY; Liu SB; Qi JJ; Dai HP; Xue SL
    Leuk Res; 2024 Apr; 139():107483. PubMed ID: 38493755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
    Venugopal S; DiNardo CD; Loghavi S; Qiao W; Ravandi F; Konopleva M; Kadia T; Bhalla K; Jabbour E; Issa GC; Macaron W; Daver N; Borthakur G; Montalban-Bravo G; Yilmaz M; Patel KP; Kanagal-Shamanna R; Chien K; Maiti A; Kantarjian H; Short NJ
    Am J Hematol; 2022 Dec; 97(12):1560-1567. PubMed ID: 36087091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
    Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
    Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
    Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
    Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
    Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
    Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
    Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
    Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
    Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.
    Wang B; Hua X; Zhang J; Gu W; Li H
    Cancer Med; 2023 Apr; 12(8):9420-9433. PubMed ID: 36808479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
    Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1
    Fan GL; Jiang PJ; Yuan M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1510-1515. PubMed ID: 33067946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
    Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
    Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
    [No Abstract]   [Full Text] [Related]  

  • 13. Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia.
    Han H; Yao Y; Wang H; Zhou M; Zhang Z; Xu X; Qi J; Liu Y; Wu D; Han Y
    Cancer; 2023 Jan; 129(2):245-254. PubMed ID: 36370049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
    Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
    Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations].
    Chen SF; Wang TZ; Jiang SH; Shen HJ; Xu Y; Zhou HF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):983-988. PubMed ID: 30612398
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
    Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 19. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.
    Xiao J; Xie J; Zhou B; Liu Y; Lu J; Jiang A; Yao H; Qiu Q; Ding Z; Xue S; Tang X; Qiu H; Chen S; Shen H; Wu D; Xu Y
    Leuk Lymphoma; 2023 May; 64(5):951-961. PubMed ID: 36964663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis.
    Rungjirajittranon T; Siriwannangkul T; Kungwankiattichai S; Leelakanok N; Rotchanapanya W; Vittayawacharin P; Mekrakseree B; Kulchutisin K; Owattanapanich W
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.